Naumann R W, Alvarez R D, Partridge E E, Kilgore L C, Austin J M
Department of Obstetrics and Gynecology, University of Alabama at Birmingham 35233-7333.
Gynecol Oncol. 1993 Sep;50(3):291-3. doi: 10.1006/gyno.1993.1213.
With the development of new intraperitoneal treatments in ovarian cancer, safe and convenient access to the peritoneal cavity is now required. This report reviews the University of Alabama at Birmingham's experience with the Groshong catheter as an intraperitoneal access device. The Groshong was easily inserted intraperitoneally in 20 ovarian cancer patients and used to deliver 81 courses of intraperitoneal therapy over 2310 patient-days. There were no catheter-related complications during treatment and only one exit site infection after catheter removal. Further investigation of the Groshong catheter as a novel intraperitoneal access device appears warranted.
随着卵巢癌新型腹腔内治疗方法的发展，现在需要安全便捷地进入腹腔。本报告回顾了阿拉巴马大学伯明翰分校使用Groshong导管作为腹腔内接入装置的经验。Groshong导管在20例卵巢癌患者中很容易经腹腔插入，并在2310个患者日期间用于进行81个疗程的腹腔内治疗。治疗期间没有与导管相关的并发症，导管拔除后仅发生1例出口部位感染。对Groshong导管作为一种新型腹腔内接入装置进行进一步研究似乎是有必要的。
